{
    "clinical_study": {
        "@rank": "105996", 
        "arm_group": [
            {
                "arm_group_label": "Mebendazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21)."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of mebendazole compared\n      with placebo in pediatric participants with Helminth infections."
        }, 
        "brief_title": "A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Helminth Infections", 
        "condition_browse": {
            "mesh_term": "Helminthiasis"
        }, 
        "detailed_description": {
            "textblock": "This will be a double-blind (neither physician nor participant knows the treatment that the\n      participant receives), randomized (the study drug is assigned by chance), multi-center,\n      parallel-group study (each group of participants will be treated at the same time) to\n      evaluate the efficacy and safety of mebendazole (a drug currently being investigated for\n      Helminth gastrointestinal infections) compared with placebo (an inactive substance that is\n      compared with a drug to test whether the drug has a real effect in a clinical trial) in\n      children (including pre-school and school-aged children) with Helminth infections.  The\n      study will consist of 3 phases: a screening phase, a double-blind treatment phase, and a\n      post-treatment (or follow-up) phase.  A pharmacokinetic (explores what a drug does to the\n      body) open-label substudy (asks a separate research question from the parent study while\n      using the same participant population but does not contribute to the parent study's\n      objectives) will be included in the parent study to measure the level of mebendazole in the\n      blood. Safety assessments will be performed throughout the study. Each participant will take\n      part in the study for approximately 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female participants who are >=9 years old must have a negative urine pregnancy test\n             at screening or at the time of randomization\n\n          -  Participants must be an otherwise healthy child, based on medical history, physical\n             examination, vital signs, hemoglobin, and concomitant medications\n\n          -  Participants >=3 years of age must have teeth and be able to chew\n\n          -  Participant must be available to return to the study site for all visits, including\n             the follow-up visit\n\n          -  Parent(s)/guardians of participants (or their legally-accepted representatives) must\n             have signed an informed consent document indicating that they understand the purpose\n             of and procedures required for the study and are willing to have their child\n             participate in the study\n\n          -  Children 6 years of age and older will be asked to assent (agree) to their\n             participation using appropriate language to their level of understanding; assent will\n             be documented\n\n        Exclusion Criteria:\n\n          -  Participant has active diarrhea (defined as the passage of 3 or more loose or liquid\n             stools per day) at screening or at the time of randomization\n\n          -  Participant has a significant medical disorder, participant has difficulty in chewing\n             or swallowing\n\n          -  Participant has significant anemia (<8 g/dL)\n\n          -  Participant has significant wasting (greater than 2 standard deviations below the\n             mean World Health Organization [WHO] Child Growth Standards for weight-for-height or\n             body mass index)\n\n          -  Participant has a known hypersensitivity to mebendazole, any inert ingredients in the\n             chewable formulation\n\n          -  Participant has preplanned surgery/procedures that would interfere with the conduct\n             of the study during the course of study\n\n          -  Participants has received an investigational drug (including vaccines) or used an\n             investigational medical device within 30 days before the planned start of treatment,\n             or is currently enrolled in an investigational study\n\n          -  Employees of the investigator or study site, with direct involvement in the proposed\n             study or other studies under the direction of that investigator or study site, as\n             well as family members of the employees or the investigator\n\n          -  Participant has taken any form of medication containing mebendazole or any other\n             treatment for soil transmitted helminth infection within 30 days of entry into the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034162", 
            "org_study_id": "CR100933", 
            "secondary_id": "MEBENDAZOLGAI3003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mebendazole", 
                "description": "Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.", 
                "intervention_name": "Mebendazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mebendazole", 
                "Piperazine", 
                "Piperazine citrate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Helminth infections", 
            "Helminths", 
            "Pediatric", 
            "Preschool aged", 
            "School aged", 
            "Mebendazole", 
            "Vermox", 
            "Placebo"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gondar", 
                        "country": "Ethiopia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jimma", 
                        "country": "Ethiopia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kigali", 
                        "country": "Rwanda"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Ethiopia", 
                "Rwanda"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "This study is not yet recruiting patients. Please check back for future recruiting sites, or email"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Cure is defined as a posttreatment egg count of zero in participants who had a positive egg count at baseline.", 
                "measure": "Cure rate for A. lumbricoides for those participants with a positive egg count for that soil-transmitted helminth at baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) to Day 20"
            }, 
            {
                "description": "Cure is defined as a posttreatment egg count of zero in participants who had a positive egg count at baseline.", 
                "measure": "Cure rate for T. trichiura for those participants with a positive egg count for that soil-transmitted helminth at baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) to Day 20"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034162"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Egg count at end of treatment period minus egg count at baseline divided by egg count at baseline multiplied by 100%.", 
                "measure": "The percentage egg reduction for A. lumbricoides for those participants with a positive egg count for that soil-transmitted helminth at baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) to Day 20"
            }, 
            {
                "description": "Egg count at end of treatment period minus egg count at baseline divided by egg count at baseline multiplied by 100%.", 
                "measure": "The percentage egg reduction for T. trichiura for those participants with a positive egg count for that soil-transmitted helminth at baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) to Day 20"
            }
        ], 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}